Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SABRATEK CORP (SBTK) -- Ignore unavailable to you. Want to Upgrade?

To: Know Genius who wrote (95)	5/28/1999 8:08:00 AM
From: Mike	Respond to of 487

ROCAP IS REAPPROVED. I just read a press release from the Yahoo SBTK board that it was announced 25 minutes ago!!!!!!! The Rocap prefilled syringes for saline are approved and the FDA has closed out the warning letter. One key point is that the heparin prefilled syringes are not approved. The Rocap prefilled saline syringes are 70% of the business for Rocap but the other 30% will still have to wait. Was this expected? In addition, has everyone read the Street.com article on SBTK's balance sheet? This article,which I have not read,was very negative on SBTK's balance sheet. Does anyone have access to the actual article and can post it? If not can anyone give us a synopsis? Is there another viewpoint are on the balance sheet or is the article justified? Let us know. Well this is great news and I am long but still have the following concerns. First is can management be trusted and is this a house of accounting cards? If Rocap ends up being a blowout in terms of sales it can correct many problems. In the meantime SBTK can get the balance sheet in order. Let us know, Mike